PRP Treatment for Erectile Dysfunction

Erectile dysfunction (ED) has established treatments from oral phosphodiesterase type 5 inhibitors through penile prosthesis surgery. Intracavernosal platelet-rich plasma (PRP) is an investigational option. A 2023 review in Sexual Medicine Reviews found the safety profile generally acceptable but could not settle efficacy because trial methods differed widely.

Erectile dysfunction in brief

ED is the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It often coexists with diabetes and cardiovascular disease. Guideline-supported options include oral medication, vacuum devices, intraurethral and injectable agents, and implants. See 8 treatment types for ED and the AUA guideline’s full spectrum of options.

What PRP is

Platelet-rich plasma is a concentrated platelet fraction prepared from a patient’s own blood. Platelets release growth factors involved in tissue repair. The investigational idea for ED is that injecting PRP into the corpora cavernosa (intracavernosal injection) might support tissue recovery. That mechanism is plausible; it is not the same as a demonstrated clinical benefit.

What the 2023 review found

Fazekas and colleagues reviewed the research on intracavernosal PRP for ED and identified four randomized clinical trials of safety and effectiveness.

• PRP preparation methods, dosing, and follow-up intervals differed substantially across the four trials.
• The safety profile was generally acceptable.
• Because of that methodological variation, the authors could not draw a firm conclusion on efficacy.

Guideline status and next steps

The 2018 AUA Erectile Dysfunction Guideline classifies PRP as experimental (Statement 25, Expert Opinion). Until larger, standardized trials report consistent outcomes, PRP should not be presented as an established ED therapy. Men considering it should ask how a given clinic prepares and doses PRP, what follow-up is planned, and how results will be measured — ideally with a validated questionnaire such as those described in validated questionnaires for ED.

References

• Fazekas D, Campbell K, Ledesma B, Masterson T. Platelet-rich plasma for erectile dysfunction: a review of the current research landscape. Sexual Medicine Reviews. 2023;11(4):369–374.
• American Urological Association. Erectile Dysfunction Guideline (2018), Statement 25.

If you have questions about anything in this article, write to us at hello@xialla.com. We read and answer every message.